<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453933</url>
  </required_header>
  <id_info>
    <org_study_id>RASSTER2010</org_study_id>
    <nct_id>NCT01453933</nct_id>
  </id_info>
  <brief_title>RAltegravir Switch STudy: Effects on Endothelial Recovery</brief_title>
  <acronym>RASSTER</acronym>
  <official_title>Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication &lt;50 Copies/ml</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with HIV-infection with protease inhibitors is associated with high blood lipids
      and higher chance for cardiovascular complications. The RASSTER study aims to investigate the
      effect of switching the protease inhibitor lopinavir/ritonavir to raltegravir on vessel wall
      function and inflammation,and activation of the immune system. we hypothesize that with this
      intervention these parameters will improve. Since decreased vessel wall function and
      inflammation are initial steps in the process of atherosclerosis, it is important to know
      this data when treating HIV-infected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fixed dose combination lopinavir/ritonavir (LPV/r) is a widespread used antiretroviral drug
      belonging to the class of protease inhibitors (PIs). PIs are associated with an increased
      risk of myocardial infarction. However, data is available suggesting increased levels of
      plasma lipids are not the sole explanation for this observation. Treatment with LPV/r might
      lead to a decrease of endothelial function as well, thus explaining the increased risk of
      myocardial infarction besides increased plasma lipids. Raltegravir is a registered
      antiretroviral drug with no known cardiovascular side effects. We hypothesize that switching
      LPV/r to raltegravir in HIV-infected patients with suppressed plasma viral load (&lt;50
      copies/ml) will lead to an improvement of endothelial function.

      Objective:

        -  First, to assess the effect of the switch of lopinavir/ritonavir to raltegravir on
           endothelial function.

        -  Second, to assess the effect of the intervention mentioned above on markers of
           endothelial function; immune activation; chronic inflammation; and, on plasma HIV-RNA
           below the cut-off of 50 copies/ml.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in flow mediated dilatation (FMD) of the brachial artery</measure>
    <time_frame>week 8, week16</time_frame>
    <description>Change in flow-mediated dilatation (FMD) of the brachial artery after 8 weeks of raltegravir treatment as compared to the control group (treatment with lopinavir/ritonavir)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in markers of chronic inflammation</measure>
    <time_frame>Baseline, week 2, week 4, week 8, week 10, week 12 and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of immune activation</measure>
    <time_frame>Baseline, week 2, week 4, week 8, week 10, week 12 and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of endothelial function</measure>
    <time_frame>Baseline, week 2, week 4, week 8, week 10, week 12 and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma HIV-RNA below 50 copies/ml</measure>
    <time_frame>Baseline, week 8, week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>HIV Infection</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At baseline, lopinavir-ritonavir will be switched to raltegravir (cross-over after 8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lopinavir/ritonavir</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will continue lopinavir/ritonavir (cross-over after 8 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)</description>
    <arm_group_label>Raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  HIV-1 infection

          -  Treatment with antiretroviral regimen containing lopinavir/ritonavir for at least the
             previous 3 months

          -  No other protease inhibitors besides lopinavir/ritonavir in antiretroviral regimen

          -  Subjects must have a minimum period of viral suppression (plasma HIV-RNA &lt; 50
             copies/ml) of 6 months

          -  Subjects will not have a history of virological failure on antiretroviral therapy

          -  Results of previous resistance testing allowing replacement of lopinavir/ritonavir by
             raltegravir

          -  CD4+ cell count &gt; 200 cells/µL

          -  Signed informed consent

        Exclusion Criteria:

          -  Pregnancy

          -  Breastfeeding

          -  Raltegravir hypersensitivity

          -  Treatment of underlying malignancy

          -  Renal insufficiency requiring dialysis

          -  Acute or decompensated chronic hepatitis (Child-Pugh score C)

          -  Modification of antiretroviral regimen in the previous 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andy IM Hoepelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Utrecht, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven FL van Lelyveld, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Utrecht, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven FL van Lelyveld, MD</last_name>
    <email>s.f.l.vanlelyveld@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andy IM Hoepelman, MD, PhD</last_name>
    <email>i.m.hoepelman@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido van den Berk, MD, PhD</last_name>
      <email>G.E.L.vandenBerk@olvg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven FL van Lelyveld, MD</last_name>
      <email>s.f.l.vanlelyveld@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Andy IM Hoepelman, MD, PhD</last_name>
      <email>i.m.hoepelman@umcutrecht.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Steven FL van Lelyveld, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andy IM Hoepelman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2011</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>S.F.L. van Lelyveld</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Anti-Retroviral Agents</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Lopinavir/ritonavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

